NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company focused on developing treatments for severe neurological and psychiatric conditions, including bipolar depression, along with COVID-19-related respiratory complications. The company became publicly traded through its business combination with Big Rock Partners Acquisition Corp (BRPA), a blank-check vehicle sponsored by Big Rock Partners LLC that completed its IPO in 2018. This 10-Q, filed November 16, 2020, captures the company's quarterly financials as it advanced its drug development pipeline in the healthcare sector. For complete filing histories, deal timelines, and real-time SPAC intelligence on NRXP, sign up for full data access at SpacDesk.